Emergency drug use in a pandemic: Harsh lessons from COVID-19 | Zendy

Gail Brenda Cross | Zendy; Jessica Ho | Zendy; William J. Zacharias | Zendy; Anand D. Jeyasekharan | Zendy; Ivan Marazzi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emergency drug use in a pandemic: Harsh lessons from COVID-19

Author(s) -

Gail Brenda Cross,

Jessica Ho,

William J. Zacharias,

Anand D. Jeyasekharan,

Ivan Marazzi

Publication year - 2021

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2021.09.025

Subject(s) - pandemic , covid-19 , biology , drug development , work (physics) , drug , key (lock) , virology , infectious disease (medical specialty) , outbreak , pharmacology , ecology , medicine , disease , engineering , mechanical engineering , pathology

The scientific and clinical communities have both experienced several harsh lessons on clinical care management and drug development during the COVID-19 pandemic. Here, we discuss several key lessons learned and describe a framework within which our two communities can work together and invest in to improve future pandemic responses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research